AU2019374773B2 - Methods and compositions for treating infectious, autoimmune, and allergic disease - Google Patents

Methods and compositions for treating infectious, autoimmune, and allergic disease

Info

Publication number
AU2019374773B2
AU2019374773B2 AU2019374773A AU2019374773A AU2019374773B2 AU 2019374773 B2 AU2019374773 B2 AU 2019374773B2 AU 2019374773 A AU2019374773 A AU 2019374773A AU 2019374773 A AU2019374773 A AU 2019374773A AU 2019374773 B2 AU2019374773 B2 AU 2019374773B2
Authority
AU
Australia
Prior art keywords
cma
bacteria
healthy
caccae
true
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019374773A
Other languages
English (en)
Other versions
AU2019374773A1 (en
Inventor
Dionysios Antonopoulos
Riyue BAO
John W. COLSON
Lauren Anders HESSER
Cathryn R. NAGLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clostrabio
University of Chicago
Original Assignee
Clostrabio
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clostrabio, University of Chicago filed Critical Clostrabio
Publication of AU2019374773A1 publication Critical patent/AU2019374773A1/en
Application granted granted Critical
Publication of AU2019374773B2 publication Critical patent/AU2019374773B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
AU2019374773A 2018-11-05 2019-11-05 Methods and compositions for treating infectious, autoimmune, and allergic disease Active AU2019374773B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862755945P 2018-11-05 2018-11-05
US62/755,945 2018-11-05
PCT/US2019/059865 WO2020097077A1 (en) 2018-11-05 2019-11-05 Methods and compositions for treating infectious, autoimmune, and allergic disease

Publications (2)

Publication Number Publication Date
AU2019374773A1 AU2019374773A1 (en) 2021-06-10
AU2019374773B2 true AU2019374773B2 (en) 2025-10-16

Family

ID=70611079

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019374773A Active AU2019374773B2 (en) 2018-11-05 2019-11-05 Methods and compositions for treating infectious, autoimmune, and allergic disease

Country Status (9)

Country Link
US (1) US12589122B2 (cg-RX-API-DMAC7.html)
EP (1) EP3876755A4 (cg-RX-API-DMAC7.html)
JP (1) JP7737098B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210098464A (cg-RX-API-DMAC7.html)
CN (1) CN113271796A (cg-RX-API-DMAC7.html)
AU (1) AU2019374773B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021008767A2 (cg-RX-API-DMAC7.html)
CA (1) CA3118679A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020097077A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113271796A (zh) 2018-11-05 2021-08-17 芝加哥大学 用于治疗感染性、自身免疫和过敏性疾病的方法和组合物
WO2022020852A1 (en) * 2020-07-22 2022-01-27 The University Of Chicago Methods and compositions for treating autoimmune and allergic disorders
US11334352B1 (en) 2020-12-29 2022-05-17 Kpn Innovations, Llc. Systems and methods for generating an immune protocol for identifying and reversing immune disease
JP7124148B1 (ja) * 2021-03-08 2022-08-23 Ｖａｒｉｎｏｓ株式会社 微生物叢のメタゲノム解析
EP4426354A4 (en) * 2021-11-03 2025-10-08 Univ Chicago PRODRUG COPOLYMERS AND POLYMERIC MICELLES THEREOF FOR DELIVERY OF SHORT-CHAIN FATTY ACIDS, PROMOTION OF GUT HEALTH, AND TREATMENT OF IMMUNE AND/OR INFLAMMATORY CONDITIONS AND FOOD ALLERGY
WO2025183115A1 (ja) * 2024-02-28 2025-09-04 三菱ケミカル株式会社 乳酸産生菌及び酪酸産生菌を含む整腸用組成物
CN120843703A (zh) * 2025-07-24 2025-10-28 上海市生物医药技术研究院 一种利用癌组织的特定微生物预测乳腺癌原位复发的方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095241A2 (en) * 2013-12-16 2015-06-25 Seres Health, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
WO2016070151A1 (en) * 2014-10-31 2016-05-06 Whole Biome. Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
US20160271189A1 (en) * 2015-03-18 2016-09-22 Whole Biome, Inc. Methods and compositions relating to microbial treatment and diagnosis of skin disorders
WO2018057914A1 (en) * 2016-09-22 2018-03-29 The University Of Chicago Immune response modulation using live biotherapeutics, for conditions such as allergy desensitization
WO2018106844A1 (en) * 2016-12-06 2018-06-14 Whole Biome Inc. Methods and compositions relating to isolated and purified microbes
WO2018107365A1 (zh) * 2016-12-13 2018-06-21 深圳华大基因研究院 粪厌氧棒杆菌(Anaerostipes caccae)及其应用
WO2018187272A1 (en) * 2017-04-03 2018-10-11 Gusto Global, Llc Rational design of microbial-based biotherapeutics

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0307026D0 (en) * 2003-03-27 2003-04-30 Rowett Res Inst Bacterial supplement
CA2683383C (en) 2007-02-21 2016-01-05 Allaccem, Incorporated Bridged polycyclic compound based compositions for the inhibition and amelioration of disease
ES2993669T3 (en) 2011-12-01 2025-01-03 Univ Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
US20140161878A1 (en) * 2012-12-12 2014-06-12 Sweet Wellness AB Multi-nutrient supplement and uses thereof
JP6754694B2 (ja) 2014-03-06 2020-09-16 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル プロバイオティクス製剤および使用のための方法
CN115252650A (zh) 2015-11-03 2022-11-01 布里格姆及妇女医院股份有限公司 用于治疗和/或预防食物变态反应的治疗性微生物群
EP3639834B1 (en) 2016-02-04 2023-07-12 Universiteit Gent Use of microbial communities for human and animal health
WO2018075886A1 (en) 2016-10-21 2018-04-26 The University Of Chicago Compositions and methods for inducing immune system maintenance to prevent and/or treat infections
WO2018129249A1 (en) 2017-01-05 2018-07-12 The University Of Chicago Inhibition of enteric infection through the modulation of microbiota
JP7136807B2 (ja) 2017-04-17 2022-09-13 ザ・ユニバーシティ・オブ・シカゴ ヒトの健康及び疾患の治療用途向けの短鎖脂肪酸の腸への送達用ポリマー材料
CN113271796A (zh) 2018-11-05 2021-08-17 芝加哥大学 用于治疗感染性、自身免疫和过敏性疾病的方法和组合物
ES2763874B2 (es) 2018-11-30 2020-10-13 Consejo Superior Investigacion Phascolarctobacterium faecium para su uso en la prevencion y tratamiento de la obesidad y sus comorbilidades

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095241A2 (en) * 2013-12-16 2015-06-25 Seres Health, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
WO2016070151A1 (en) * 2014-10-31 2016-05-06 Whole Biome. Inc. Methods and compositions relating to microbial treatment and diagnosis of disorders
US20160271189A1 (en) * 2015-03-18 2016-09-22 Whole Biome, Inc. Methods and compositions relating to microbial treatment and diagnosis of skin disorders
WO2018057914A1 (en) * 2016-09-22 2018-03-29 The University Of Chicago Immune response modulation using live biotherapeutics, for conditions such as allergy desensitization
WO2018106844A1 (en) * 2016-12-06 2018-06-14 Whole Biome Inc. Methods and compositions relating to isolated and purified microbes
WO2018107365A1 (zh) * 2016-12-13 2018-06-21 深圳华大基因研究院 粪厌氧棒杆菌(Anaerostipes caccae)及其应用
WO2018187272A1 (en) * 2017-04-03 2018-10-11 Gusto Global, Llc Rational design of microbial-based biotherapeutics

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Bircher, L. et al., 'Effect of cryopreservation and lyophilization on viability and growth of strict anaerobic human gut microbes', Microbial Biotechnology. 2018, vol.11, pages 721-733 *
Falony, G. et al., 'Cross-feeding between Bifidobacterium longum BB536 and acetate-converting, butyrate-producing colon bacteria during growth on oligofructose', Applied and Environmental Microbiology. 2006, vol.72, pages 7835-7841 *
Ose, O. et al., 'The ability of human intestinal anaerobes to metabolize different oligosaccharides: Novel means for microbiota modulation?', Anaerobe. 2018, vol.51, pages 110-119 *
PIETER VAN DEN ABBEELE ET AL: ENVIRONMENTAL MICROBIOLOGY, vol. 13, no. 10, 30 August 2011 (2011-08-30), GB, pages 2667 - 2680, XP055683780, ISSN: 1462-2912, DOI: 10.1111/j.1462-2920.2011.02533.x *

Also Published As

Publication number Publication date
WO2020097077A1 (en) 2020-05-14
JP2022510780A (ja) 2022-01-28
EP3876755A4 (en) 2022-08-24
JP7737098B2 (ja) 2025-09-10
CN113271796A (zh) 2021-08-17
BR112021008767A2 (pt) 2021-08-17
US20210386796A1 (en) 2021-12-16
KR20210098464A (ko) 2021-08-10
AU2019374773A1 (en) 2021-06-10
US12589122B2 (en) 2026-03-31
EP3876755A1 (en) 2021-09-15
CA3118679A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
AU2019374773B2 (en) Methods and compositions for treating infectious, autoimmune, and allergic disease
US12502411B2 (en) Proliferation or accumulation of regulatory T cells
US11672834B2 (en) Probiotic and prebiotic compositions, and methods of use thereof for modulation of the microbiome
US20230256034A1 (en) Methods and compositions for treating autoimmune and allergic disorders
Ceylan Holistic Review of the Association Between Microbiome and Immune-Mediated Inflammatory Diseases
HK40070967A (en) Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
HK40070967B (en) Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
El Morr Les cellules MAIT et la riboflavine dans les interactions hôte-microbiote
HK40102404A (zh) 诱导调节性t细胞的增殖或积累的人源细菌

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 59 , NO 34 , PAGE(S) 4784 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX DELETE ALL REFERENCE TO 2019374773.

FGA Letters patent sealed or granted (standard patent)